Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

Skip to Content

Clinical Trial Details

Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

Objective

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).

IRB Protocol Number
ECOG-ACRIN EA9161 (NCT# 03701282)

Clinical Trial Categories

  • Lymphoma/Lymph Node/Leukemia/Blood-related Cancers
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6031